Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Apricus Biosc Inc (APRI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,321
  • Shares Outstanding, K 23,440
  • Annual Sales, $ 0 K
  • Annual Income, $ 320 K
  • 36-Month Beta 1.38
  • Price/Sales 0.86
  • Price/Cash Flow N/A
  • Price/Book 1.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/01/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.25 +37.25%
on 06/05/18
0.58 -39.66%
on 06/12/18
+0.05 (+16.67%)
since 05/18/18
3-Month
0.25 +40.00%
on 05/03/18
0.73 -52.05%
on 03/21/18
-0.37 (-51.39%)
since 03/19/18
52-Week
0.25 +40.00%
on 05/03/18
3.34 -89.52%
on 02/15/18
-0.71 (-66.98%)
since 06/19/17

Most Recent Stories

More News
Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks

Stock Research Monitor: ATNM, AMRN, and APRI

AMRN : 3.18 (-0.93%)
APRI : 0.34 (-2.86%)
ATNM : 0.60 (-4.76%)
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2018...

APRI : 0.34 (-2.86%)
Dthera Sciences Appoints Steve R. Martin to Board of Directors

SAN DIEGO, CA / ACCESSWIRE / April 16, 2018 / Dthera™ Sciences (OTCQB: DTHR), a digital therapeutics company focused on developing the innovative quality of life therapies for the elderly and those suffering...

APRI : 0.34 (-2.86%)
DTHR : 0.4377 (+0.55%)
DTHRD : N/A (unch)
Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA

FDA Confirms Vitaros Regulatory Pathway

APRI : 0.34 (-2.86%)
Apricus Biosciences Announces Closing of $3.55 Million Public Offering

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the closing of its previously announced public offering...

APRI : 0.34 (-2.86%)
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has...

APRI : 0.34 (-2.86%)
Apricus Biosciences Announces Proposed Public Offering

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a public offering of shares of common...

APRI : 0.34 (-2.86%)
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review meeting with the U.S. Food and Drug...

APRI : 0.34 (-2.86%)
Blog Exposure - Cipher to Acquire Cardiome's Canadian Business Portfolio for $25.5 Million in Cash

Stock Monitor: Apricus Biosciences Post Earnings Reporting

APRI : 0.34 (-2.86%)
CRME : 2.33 (-2.10%)
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Amarin, Apricus Biosciences, United Therapeutics, and Novo Nordisk

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AMRN, APRI, UTHR, and NVO which can be accessed for free by signing up to www.wallstequities.com/registration....

AMRN : 3.18 (-0.93%)
NVO : 44.70 (-0.11%)
APRI : 0.34 (-2.86%)
UTHR : 116.97 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade APRI with:

Business Summary

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the...

See More

Key Turning Points

2nd Resistance Point 0.40
1st Resistance Point 0.38
Last Price 0.34
1st Support Level 0.34
2nd Support Level 0.33

See More

52-Week High 3.34
Fibonacci 61.8% 2.16
Fibonacci 50% 1.79
Fibonacci 38.2% 1.43
Last Price 0.34
52-Week Low 0.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar